# Recent Strategies to Attenuate Hepatocellular Carcinoma Recurrence After Liver Transplantation: A Narrative Review

## TL;DR

This paper reviews strategies to reduce liver cancer recurrence after liver transplants, focusing on risk factors, selection criteria, and treatment options.

## Contribution

The paper provides a comprehensive review of recent strategies to manage hepatocellular carcinoma recurrence after liver transplantation.

## Key findings

- Tumor-related factors like poor differentiation and vascular invasion increase recurrence risk.
- Multidisciplinary approaches are essential for managing recurrent HCC after liver transplantation.
- Systemic therapies like sorafenib and regorafenib offer modest benefits for advanced recurrent HCC.

## Abstract

Hepatocellular carcinoma (HCC) is one of the main reasons for liver transplants, but up to 15% of patients experience recurrence after surgery. Factors like poor tumor differentiation, vascular invasion, and high alpha-fetoprotein levels increase the recurrence risk. Donor-related factors also play a role, though their impact is less clear. Selection criteria, such as the Milan Criteria and RETREAT score, help predict recurrence risk. Treatment options for recurrent HCC include surgery for localized cases, locoregional therapies like ablation and chemoembolization, and systemic treatments such as targeted drugs (sorafenib, regorafenib, lenvatinib). Immunotherapy shows potential but is complicated by the need for immunosuppression. A multidisciplinary approach is key to managing recurrence, and future research should focus on better prediction tools and new therapies to improve patient outcomes.

Hepatocellular carcinoma (HCC) is one of the leading causes of liver transplant worldwide. While liver transplantation offers a survival advantage for early-stage HCC patients, post-transplant recurrence remains a significant concern, affecting up to 15% of recipients. We sought to conduct a comprehensive review related to HCC recurrence after liver transplant. Tumor-related factors such as poor differentiation, vascular invasion, and elevated tumor biomarkers like alpha-fetoprotein are key predictors of recurrence. Donor-related factors, including graft type and surgical procedures, can also influence outcomes, though their effects are less conclusive. Advancements in patient selection criteria and scoring systems, such as the Milan Criteria and RETREAT score, have improved risk stratification by incorporating tumor size, biomarkers, and response to pre-transplant treatment. Despite these measures, recurrent HCC after transplantation poses treatment challenges. Curative approaches such as resection are feasible for localized or oligometastatic recurrence and offer the best outcomes when applicable. Locoregional treatments, including ablation and transarterial chemoembolization, provide options for unresectable cases but have limited long-term efficacy. Systemic therapies, including targeted agents like sorafenib, regorafenib, and lenvatinib, have shown modest benefits in managing advanced recurrent HCC. Emerging immunotherapy approaches hold promise but face unique challenges due to the required immunosuppression in transplant recipients. Multidisciplinary evaluation remains essential for tailoring treatment plans. Future efforts should focus on refining predictive tools and exploring novel therapies to improve survival outcomes for patients with recurrent HCC after liver transplantation.